Patients with relapsed/refractory follicular lymphoma experienced durable responses when treated with tisagenlecleucel (Kymriah) in the phase 2 ELARA study (NCT03568461), according to data presented at the 2023 ASH Annual Meeting.

Related Keywords

, Stephenj Schuster , Margarita Louis Dreyfus Professor , Chronic Lymphocytic Leukemia , Lymphoma Clinical Care , Cash , Tisagenlecleucel , Follicular Lymphoma , Elara Study , Relapsed Refractory Follicular Lymphoma , Kymriah ,